## KLE\_CELL\_DISEASE\_DN, JISON\_SICKLE\_CELL\_DISEASE\_DN (

BILANGES\_SERUM\_AND\_RAPAMYCIN\_SENSITIVE\_GENES, BILANGES\_SERUM\_AND\_RAPAMYCIN\_SE IRITANI\_MAD1\_TARGETS\_DN, IRITANI\_MAD1\_TARGETS\_DN TIEN\_INTESTINE\_PROBIOTICS\_6HR\_UP, TIEN\_INTESTINE\_PROBIOTICS\_6HR\_UP ALCALA APOPTOSIS, ALCALA APOPTOSIS DUNNE\_TARGETS\_OF\_AML1\_MTG8\_FUSION\_UP, DUNNE\_TARGETS\_OF\_AML1\_MTG8\_FUSION\_UP YAMASHITA\_LIVER\_CANCER\_WITH\_EPCAM\_UP, YAMASHITA\_LIVER\_CANCER\_WITH\_EPCAM\_UP CHNG\_MULTIPLE\_MYELOMA\_HYPERPLOID\_UP, CHNG\_MULTIPLE\_MYELOMA\_HYPERPLOID\_UP ZHONG\_RESPONSE\_TO\_AZACITIDINE\_AND\_TSA\_DN, ZHONG\_RESPONSE\_TO\_AZACITIDINE\_AND\_T MARIADASON\_RESPONSE\_TO\_BUTYRATE\_SULINDAC\_6, MARIADASON\_RESPONSE\_TO\_BUTYRATE\_ MUELLER\_COMMON\_TARGETS\_OF\_AML\_FUSIONS\_UP, MUELLER\_COMMON\_TARGETS\_OF\_AML\_FU HOLLEMAN ASPARAGINASE RESISTANCE B ALL UP, HOLLEMAN ASPARAGINASE RESISTANCE I HOLLEMAN\_ASPARAGINASE\_RESISTANCE\_ALL\_UP, HOLLEMAN\_ASPARAGINASE\_RESISTANCE\_AL LINDGREN BLADDER CANCER CLUSTER 1 UP, LINDGREN BLADDER CANCER CLUSTER 1 UP NUTT\_GBM\_VS\_AO\_GLIOMA\_DN, NUTT\_GBM\_VS\_AO\_GLIOMA\_DN LUI\_THYROID\_CANCER\_CLUSTER\_3, LUI\_THYROID\_CANCER\_CLUSTER\_3 BORCZUK MALIGNANT\_MESOTHELIOMA\_DN, BORCZUK\_MALIGNANT\_MESOTHELIOMA\_DN SIMBULAN\_UV\_RESPONSE\_IMMORTALIZED\_DN, SIMBULAN\_UV\_RESPONSE\_IMMORTALIZED\_DN CROMER\_METASTASIS\_UP, CROMER\_METASTASIS\_UP DIRMEIER\_LMP1\_RESPONSE\_LATE\_DN, DIRMEIER\_LMP1\_RESPONSE\_LATE\_DN VANTVEER BREAST CANCER ESR1 UP, VANTVEER BREAST CANCER ESR1 UP